Ryvu Therapeutics SA · LSX:A1JUH2

Ryvu Therapeutics SA financial statements

Ryvu Therapeutics SA's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in PLN

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue62.3M78.0M46.9M38.8M11.2M15.4M42.6M77.2M87.8M48.1M
Cost of revenue179.3M19.6M17.6M17.4M13.7M8.76M92.7M29.7M25.9M16.9M
Gross profit-117.0M58.4M29.3M21.4M-2.54M6.65M-50.2M47.6M61.9M31.3M
Research and development26.0M15.0M13.0M67.6M53.9M27.1M17.3M
Selling, general and administrative5.56M4.33M5.47M55.8M22.1M17.9M10.5M
Operating income-122.2M-122.1M-100.9M-78.4M-103.8M-35.7M-45.1M-13.6M12.6M-1.21M
Depreciation and amortization9.44M10.5M11.0M12.9M12.6M12.4M7.99M7.09M5.24M3.62M
EBITDA-112.7M-111.6M-90.0M-65.5M-91.2M-23.3M-37.2M-6.52M17.9M2.40M
Interest expense8.80M3.81M97.0K1.09M442.0K387.4K398.3K291.5K231.2K35.8K
Income before tax-101.1M-111.1M-92.1M-79.2M-79.0M-30.6M-36.0M8.99M9.60M-1.28M
Income tax88.0K297.0K4.59M115.9K1.07M-30.0K8.09M2.87M-3.97M
Net income-101.2M-111.4M-92.1M-83.8M-79.1M-31.7M-36.0M-106.3K6.41M2.72M
Earnings per share, basic-4.38-4.82-4.02-4.57-4.31-1.89-2.25-0.010.470.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents59.6M160.1M57.9M101.9M83.2M136.2M72.1M110.4M36.1M29.1M
Short-term investments48.1M65.9M175.7M528.0K4.99M25.0M-196.0K-196.0K
Receivables20.1M20.9M9.19M5.05M11.7M7.95M15.0M21.4M19.8M16.4M
Inventory1.33M1.21M2.12M1.76M1.96M1.68M1.59M1.99M1.59M1.40M
Current assets139.3M272.4M278.4M367.9M104.2M172.4M90.0M173.2M59.9M47.7M
Property, plant and equipment91.2M91.2M66.2M39.7M31.4M21.8M
Goodwill280.7K280.7K280.7K
Total assets224.4M378.8M403.2M475.0M228.8M295.6M182.9M255.7M103.6M89.1M
Accounts payable16.2M31.1M23.1M12.6M11.7M6.26M13.4M16.7M9.37M6.79M
Current liabilities61.6M107.9M69.7M44.8M36.2M33.8M30.6M35.6M26.8M18.9M
Long-term debt70.3M73.3M00742.4K1.55M2.36M3.17M3.98M4.79M
Total debt71.7M75.5M906.0K2.77M5.07M7.41M9.22M13.5M7.99M9.62M
Total liabilities153.7M234.9M143.6M131.6M59.4M71.9M63.1M60.8M39.6M33.4M
Shareholders' equity53.8M143.9M259.6M343.4M161.3M223.7M119.8M191.9M62.3M55.4M
Shares outstanding23.1M23.1M22.9M18.3M18.4M16.8M16.0M15.5M13.8M13.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-110.3M-129.5M-84.5M21.3M-57.9M-10.6M-17.4M-36.4M11.0M-6.28M
Capital spending-7.47M-5.90M-8.58M-9.29M-12.0M-34.2M-24.0M-23.4M-21.6M-21.2M
Free cash flow-117.8M-135.4M-88.1M12.0M-69.8M-44.8M-41.4M-59.9M-10.6M-27.5M
Cash from investing13.3M137.2M-195.5M690.0K8.06M-55.9M-7.94M-37.2M-21.5M-18.4M
Cash from financing-3.05M94.2M240.8M-2.46M-3.17M130.7M2.59M147.9M17.6M25.0M
Share buybacks143.1M-2.99M134.2M935.9K327.9K
Change in cash-100.5M102.1M-44.0M18.7M-53.0M64.1M-22.8M74.2M7.03M288.1K